Objective: Little is known about the evolution of program outcomes associated with rapid expansion of antiretroviral therapy (ART) in resource-limited settings. We describe temporal trends and assess associations with mortality and loss to follow-up (LTFU) in HIV cohorts from 8 countries.
INTRODUCTION
Over the past decade, there has been rapid expansion of antiretroviral therapy (ART) in resource-limited settings. By 2011, an estimated 9.7 million people in low-and middleincome countries were receiving ART. 1 During this growth, HIV programs have adapted services to cope with the increasing numbers of patients requiring ART. As programs mature and increase in size, the need to ensure long-term retention in care of patients receiving ART while continuing timely initiation of new patients onto treatment presents an ongoing challenge to policy makers and health-care providers alike.
Over the past decade, the conditions in which ART programs operate in low-and middle-income countries have changed considerably. The numbers of patients have increased rapidly and often disproportionately to the number of health-care workers providing care. 2 Guidelines for the initiation of ART have been simplified, and context-specific recommendations have been adapted to facilitate improving and expanding access to treatment. Furthermore, eligibility criteria for ART initiation have evolved, and recommended CD4 count thresholds for starting treatment have recently been increased to improve patient outcomes. 3 The effectiveness of ART in reducing morbidity and mortality depends on patient adherence to therapy and on the ability of HIV programs to retain patients in care. Previous analyses examining temporal trends in long-term program outcomes in resource-limited settings have reported conflicting results. Whereas data from South Africa showed increasing loss to follow-up (LTFU) by calendar year of enrollment, [4] [5] [6] systematic reviews of sub-Saharan African cohorts and findings from a large Kenyan cohort reported improvements in patient retention in recent years. [7] [8] [9] Evaluating program outcomes, assessing temporal trends in program retention, and investigating the factors associated with poor outcomes are essential to improve the long-term effectiveness of ART services in lowand middle-income countries. Understanding associations between program expansion and treatment outcomes is particularly relevant in the context of the "Treatment 2.0" initiative to scale-up HIV treatment through promoting innovation and efficiency gains and of the ambitious goal of expanding ART to 15 million people by 2015. 1, 10 The objective of this study was to describe temporal trends in patient characteristics at ART initiation and in ART outcomes using data from resource-limited countries where Médecins Sans Frontières (MSF) supports the provision of HIV treatment. We also examined associations between individual-level risk factors, absolute program size, and rate of ART program expansion and mortality and LTFU.
METHODS

Study Population
We analyzed patient electronic health records from 25 sites in 8 countries where MSF supports the provision of ART care. Cohorts were located in Democratic Republic of Congo, India, Kenya, Malawi, Mozambique, Myanmar, Uganda, and Zimbabwe. Details of these programs have been described previously. 11 All programs provided care and treatment free of charge. Criteria for ART initiation followed World Health Organization (WHO) guidelines. The analysis included all adults 16 years or older who initiated ART between March 2001 and September 2011 in one of the programs.
Data Collection and Definitions
Characteristics at ART initiation, including sex, age, CD4 cell counts, WHO clinical stage, body mass index (BMI), and date of ART initiation were prospectively collected with the FUCHIA software (Epicentre, Paris, France). Throughout, reference to baseline is a reference to time of ART initiation.
Patient follow-up began at the date of ART initiation and was censored at the earliest of death, transfer out, last clinic visit, or analysis closure. Sites began initiating patients onto ART between 2001 and 2007. Only patients with a minimum of 6 months of follow-up were included with analysis closure preceding the database closure date by 6 months. The database closure ranged from September 30, 2011 , to March 20, 2012 . Deaths were events recorded before the analysis closure date. LTFU was defined as having no visit in the 6 months before analysis closure. Patients who initiated treatment but did not return were given 1 day of follow-up time so that they would contribute to survival analysis. 12 Program retention was defined as being in care (ie, not dead or LTFU) at the time of analysis closure.
To quantify the size of the ART programs, 2 variables, program size and the rate of program expansion, were defined. For each patient, program size was calculated as the total number of both pre-ART and ART patients receiving care in the program at the end of the calendar year of patient ART initiation. To define the rate of program expansion, the rank of each patient enrolled by site was divided by the duration of ART provision in the site up to the date of enrollment, in months. For example, if the 100th patient at the site was enrolled 4 months after the program started, the rate of program expansion for that patient would be 25 (100/4).
Statistical Methods
Baseline characteristics were described by year of ART initiation using medians and interquartile ranges for continuous variables and proportions for categorical variables. Kaplan-Meier methods were used to describe cumulative probabilities of death, LTFU, and program retention after ART initiation and were analyzed overall, by calendar year of ART start, program size, and rate of expansion.
Cox proportional hazards models were used to assess associations between baseline patient characteristics and outcomes. Heterogeneity across sites was accounted for using random effects. To examine differences in risk factors over time, models were stratified by early (0-12 months) and late (12-72 months) follow-up periods. Adjusted models were built first by including all baseline characteristics (model 1) and then adding the program size variable (model 2), the rate of expansion variable (model 3), or both (model 4). The primary analysis only included patients with complete data on baseline characteristics (complete case analysis).
In sensitivity analyses, models including patients with missing baseline CD4 cell counts, clinical stage, and/or BMI as separate categories were used. We also assessed different measures of program size, including the number of patients who had previously initiated ART by site and the number of ART patients in care at each site at the end of the calendar year. Kaplan-Meier survival proportions and hazard ratios (HRs) stratified by site were assessed and compared with the primary results. Finally, to account for nondifferential censoring (eg, higher risk of death among patients LTFU early after ART start), models of time to death and LTFU were calculated using competing risk methods. 
Temporal Changes in Patient Baseline Characteristics and Outcomes
The number of patients initiating ART increased substantially each calendar year ( Mortality decreased over the study period (Fig. 1A) , from 17% to 5% at 12 months and from 22% to 9% at 36 months (Table 3 ). Larger programs (Fig. 1C) and those with greater rate of expansion (Fig. 1D) had lower rates of mortality. In contrast, LTFU increased substantially over time, from 6% to 15% at 12 months and from 11% to 21% at 36 months (Fig. 1B) . LTFU increased with program size up to a number of 7500 patients ( During the first year of treatment, approximately half of the program losses were LTFU patients (6% of patients had died compared with 8% who were LTFU). However, after 5 years, two-thirds of the losses were LTFU patients (24% compared with 13% of deaths). Program retention decreased from 82% at 12 months to 73% at 36 months and 66% at 60 months. The smallest programs had the largest estimates of 12-month mortality: 12%, 11%, and 9% in sites with less than 500, 500-999, and 1000-2499 people, respectively. However, 12-month LTFU was largest in medium size programs. Similarly, programs with a slow rate of expansion had double the risk of 12-month mortality compared to those with fastest expansion (10.0% vs. 5.3%). LTFU was lowest in programs with a slow rate of expansion compared those with medium or fast expansion (Fig. 1F ).
Risk Factors for Mortality
The risk of death decreased with each successive calendar year of enrollment (Table 3) Larger program size was associated with decreased early mortality (aHR = 0.49, 95% CI: 0.31 to 0.77, for $20,000 vs. ,500 patients). This association was not significant for late mortality (aHR = 0.34, 95% CI: 0.09 to 1.27) .
Fully adjusted models did not show evidence of association between rate of expansion and early or late mortality (aHR = 1.13, 95% CI: 0.87 to 1.48, and aHR = 0.85, 95% CI: 0.55 to 1.31, respectively, for $125 vs. ,25 patients per month). Increased early and late mortalities were associated with male gender (aHR = 1.30 and 1.57, respectively, for male vs. female), older age (aHR = 1.46 and 1.48, respectively, for $45 vs. 16-25 years), and low BMI (aHR = 2.59 and 1.56, respectively, for #18.5 vs. 18.6-25.0 kg/m 2 ). Death was also strongly associated with advanced clinical stage and lower CD4 count level, with the strongest associations observed with early mortality (aHR = 2.65 for stage 4 vs. 
Risk Factors for LTFU
Increased risk of early and late LTFU was observed with each successive calendar year of ART initiation (Table 4) Larger program size was associated with a 7-fold increase in the risk of early (HR = 7.35, 95% CI: 5.55 to 9.73) and late LTFU (HR = 7.03, 95% CI: 4.30 to 11.48), but the association in final models attenuated for early LTFU (aHR = 1.77, 95% CI: 1.04 to 3.04) and was not observed for late LTFU (aHR = 0.53, 95% CI: 0.27 to 1.04). Rate of program expansion was strongly associated with an increased risk of early and late LTFU (early aHR increased from 1.26 in programs with rates of 25-59 patients per month to 2.31 in those with $125 patients per month and late aHR from 1.22 to 2.29 compared with programs with rates of 0-24 patients per month, respectively). 
DISCUSSION
This multicenter cohort study included over 130,000 HIV-infected patients initiated on ART in 8 low-and middleincome countries where the provision of ART has rapidly expanded over the last 10 years. In this challenging context where programs needed to adapt to the growing numbers of patients in need for care, we observed a gradual improvement in measures of disease severity at ART initiation and a decrease in mortality over time. Despite these findings, every year, 30% of the total number of patients who initiated ART had CD4 cell counts less than 100 cells per microliter. Over the 10-year study period, ART provision was rapidly implemented and programs expanded to reach a growing number of people infected with HIV. Expansion rates ranged from 0-25 to 125-192 new patients per month and program size from ,500 to 20,000-23,995 patients. Mortality gradually improved with 6-month estimates decreasing from 14% in the years before 2004 to less than 4% in 2011, which is consistent with reports from South Africa. 4 The observed decreased estimates of mortality may result from improved access to ART, as suggested by the increased number of patients initiating ART with less severe disease. The rapid growth of programs might have also led to poorer outcome ascertainment, with greater number of deaths occurring in recent years misclassified as LTFU.
14 Linkage to national death registries is not available in these cohorts, highlighting the need to improve outcome ascertainment for program evaluation in resource-limited countries.
The rapid growth of ART programs is related to a combination of several factors, including the long-term availability of antiretroviral drugs, the implementation of new simplified guidelines for ART, and the widespread availability of CD4 enumeration to identify ART-eligible individuals. One-third of patients initiated ART with a CD4 cell count below 100, placing a substantial strain on the health-care system requiring intensive support from clinically trained staff. 15, 16 Our findings do not suggest that increases in treatment guideline thresholds prevent patients with more advanced HIV disease from accessing care but rather that all programs still face challenges in timeously seeking, testing, and linking patients to ART care.
Even with continued challenges to improving access to ART, LTFU seems to present a ubiquitous challenge to the long-term effectiveness of ART programs. After 2 years of ART, 15% of the cohort was LTFU and retention was 77%, and after 5 years of treatment, two-thirds of patients remained in care. This is slightly less than the estimate from 23 countries with cohorts of more than 2000 people, which reported 72% retention after 5 years. 1 A temporal trend of increasing LTFU was observed with LTFU contributing an increasing proportion of overall program attrition. 4, 17 These findings confirm the urgent need to refocus efforts to improve long-term retention and contradict systematic reviews from sub-Saharan Africa, suggesting that program outcomes are improving. 7, 17 A novel finding of our study is that the rate of program expansion, more than the size of the HIV program, was associated with the high levels of LTFU. This is likely to relate to the need for timely adjustments in programs to cope with the increase in activity, independently of financial and human resource allocation. Associations observed between LTFU and male gender, younger age, and advanced clinical stage are consistent with previous reports. 4, [18] [19] [20] This analysis of long-term outcomes was based on substantial follow-up of a large number of patients treated in several resource-limited ART programs. All sites offered care and treatment free of charge and followed WHO recommendations for ART initiation, and site heterogeneity was accounted for using random effects in the Cox models. These data are not likely to be representative of all ART programs because MSF provides additional resources and technical support. For example, quality and completeness of routine electronic data are challenging, but MSF provides considerable means to address these concerns. 2 Without linkage to death registries, estimates of program attrition may misclassify some proportion of deaths as LTFU. 5, 14, 18, 21, 22 LTFU may be overestimated further because of administrative errors, incomplete records of patient decentralization and unrecorded transfers, and the contribution of treatment interrupters. 2, 20, [23] [24] [25] Furthermore, we were unable to minimize this bias as we did not have data on tracing for all or a sample of those who were LTFU. 26 Our focus was limited to program outcomes after ART initiation acknowledging that a substantial proportion of patients were lost during pre-ART care. [27] [28] [29] [30] Although program size and the rate of expansion were adjusted for, residual confounding may be present if important internal organizational aspects were not sufficiently captured and from unmeasured factors. Sensitivity analyses confirmed our results investigating differences by program, including patients with missing covariate data, and adjusting for site heterogeneity. A competing risk approach led to very similar findings corroborating that the traditional Cox proportional hazards models are appropriate. 31, 32 Our findings explore the tension and challenges involved in pursuing the ambitious goals of expanding ART to 15 million people by 2015 and implementing Treatment 2.0 strategies in high-prevalence resource-limited settings. 1, 10 Recent Treatment as Prevention models assumed a longterm drop-out rate of 1.5% annually, which seems optimistic considering our estimates of long-term retention. 33 With a high burden of acutely ill patients, ART programs will struggle to expand access to patients in earlier stages of HIV disease without additional resources and a change to the models of ART delivery. With new 2013 WHO guidelines to expand ART access to an additional 9.2 million people in low-and middle-income countries, we need to fully understand the individual and programmatic implications of earlier initiation. 1 Over a decade, ART programs have expanded in highprevalence resource-limited settings with a focus to increase access to care and thus patient numbers. Today, many sites hold high numbers of HIV-infected patients, above 20,000 at some sites. The quality of ART services and psychosocial counseling at these large sites may be taking a back seat as the drive for expansion continues. The conscious trade-off between numbers and quality deserves more discussion and close monitoring as the targets for expansion of treatment continue to increase. The findings of our study suggest that, potentially, ART sites should be capped at a maximum number of patients and the rate of enrollment restricted in favor of balancing growth with quality care. Human resource capacity of the site and program organization characteristics are likely to be important determinants to consider in achieving this balance and deserve further investigation to provide effective recommendations regarding maximum patient volume and expansion rate at program level.
For the first time, the WHO guidelines acknowledge the challenge of long-term retention in ART programs with explicit guidance on operations and service delivery, including adherence, retention, decentralization, and task shifting. Additional resources are needed to strengthen monitoring systems to ascertain true outcomes of children and adults lost to care pre-and post-ART initiation.
14,34 Identification of ART patients disengaged from care is critical as they are at an increased risk of developing and transmitting drug-resistant strains of HIV. 17 There is an urgent need to determine sustainable and optimal models of care for stable patients on lifelong ART, especially in large programs in high-prevalence resource-limited settings. Decreasing visit frequency by expanding intervals between prescription refills, decentralizing ART delivery into community-based patient-led groups, and introducing flexible systems to support mobile populations are all interventions that could be considered and assessed on a large scale. [35] [36] [37] [38] In summary, ART programs in resource-limited settings have grown rapidly over the last decade. However, significant work remains to continue expanding access while addressing the growing challenge of program attrition. Sustainable models of care for long-term retention of patients in large, highprevalence resource-limited settings are urgently needed.
